DAWN — Day One Biopharmaceuticals Balance Sheet
0.000.00%
- $903.54m
- $451.96m
- $131.16m
- 62
- 23
- 71
- 51
Annual balance sheet for Day One Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 43.7 | 284 | 342 | 366 | 532 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | — | — | 13.9 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 45.1 | 289 | 348 | 375 | 562 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.483 | 0.284 | 0.719 | 0.56 | 4.71 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 45.7 | 290 | 349 | 376 | 583 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2 | 8.66 | 16.6 | 29.5 | 73.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.9 | 8.67 | 17 | 29.5 | 80 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 37.8 | 281 | 332 | 347 | 503 |
| Total Liabilities & Shareholders' Equity | 45.7 | 290 | 349 | 376 | 583 |
| Total Common Shares Outstanding |